Review Article
Pathophysiology of Motor Dysfunction in Parkinson’s Disease as the Rationale for Drug Treatment and Rehabilitation
Table 2
Nondopaminergic neurotransmitters involved in the pathogenesis of Parkinson’s disease and pharmacological agents potentially active or tested to counteract their deficit.
| ||||||||||||||||||||||||||||||||||||||||||||
5-HT: serotonin receptor 1A; : adenosine receptor A2; AMPA: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; FOG: freezing of gait; GABA: gamma-aminobutyric acid; GAD: glutamic acid decarboxylase; GP: globus pallidus; GPe: external segment of the globus pallidus; mGluNAMs: metabotropic glutamate receptor negative allosteric modulators; NMDA: N-methyl-D-aspartate; PPN: pedunculopontine nucleus; SN: substantia nigra; STN: subthalamic nucleus. |